Alexza Pharma (ALXA) Submits NDA to U.S. FDA for Staccato Loxapine Schizophrenia Treatment
Tweet Send to a Friend
Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) today announced that it has submitted its New Drug Application (NDA) for Staccato loxapine (AZ-004) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
